Eli Lilly acquires Morphic Holding for $3.2B, focusing on IBD treatment opportunities
Acquiring Company
Eli Lilly and Company
Acquired Company
Morphic Therapeutic
IndianapolisWalthamManufacturingBiotechnologyHealth CareMedicalPharmaceuticalBiotechnologyTherapeuticsBiopharmaDescription
Eli Lilly has purchased Morphic Holding for $3.2 billion, intending to leverage its expertise in the field of gastroenterology. The acquisition is in line with Lilly's commitment to developing new therapies for the benefit of patients, especially in the treatment of inflammatory bowel disease (IBD).
Quick answer
Eli Lilly and Company is acquiring Morphic Therapeutic for $3.2 billion, announced July 8, 2024. Eli Lilly and Company is based in Indianapolis, Indiana, United States.
- How much did Eli Lilly and Company pay for Morphic Therapeutic?
- The reported deal value is $3.2 billion.
- What does Eli Lilly and Company do?
- Lilly is a medicine company turning science into healing to make life better for people around the world.
- Where are Eli Lilly and Company and Morphic Therapeutic based?
- Eli Lilly and Company is based in Indianapolis, Indiana, United States. Morphic Therapeutic is based in Waltham, Massachusetts, United States.
- Who are the decision-makers at Eli Lilly and Company?
- Fundz holds 5 contacts at Eli Lilly and Company. Names and contact details are shown to Fundz members.
Source: Fundz verified event record.
Other recent acquisitions in Medical and Pharmaceutical
Deals where the buyer or target shares a sector with this one, within 45 days, from Fundz verified event records.
- Cycle Pharmaceuticals proposes to acquire Vanda Pharmaceuticals for $8.00 per share (June 6, 2024)
- Lilly Completes Acquisition of Morphic to Improve Outcomes and Expand Options for People Living with Inflammatory Bowel Disease (August 16, 2024)
- AA Medical completes acquisition of Surgical Product Solutions, forming strategic partnership (July 11, 2024)
- Lilly completes acquisition of Morphic to enhance immunology pipeline (July 8, 2024)
- Edwards Lifesciences Completes Acquisitions of JenaValve Technology and Endotronix (July 24, 2024)
- Merck completes acquisition of EyeBio to diversify its late-stage pipeline (July 12, 2024)
Who to call at Eli Lilly and Company, and when
When Eli Lilly and Company changes hands, the new owners review vendors, systems and leadership. That is when the door opens.
- An alert the day Eli Lilly and Company raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Eli Lilly and Company, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Eli Lilly and Company. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Eli Lilly and Company makes an acquisition, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
Frequently asked
Who acquired Morphic Therapeutic?
Morphic Therapeutic was acquired by Eli Lilly and Company, based in Indianapolis. The deal was reported on July 8, 2024. Lilly is a medicine company turning science into healing to make life better for people around the world. Eli Lilly and Company is publicly traded (LLY) and operates in Manufacturing.
When did Eli Lilly and Company acquire Morphic Therapeutic?
Eli Lilly and Company's acquisition of Morphic Therapeutic was reported on July 8, 2024. Eli Lilly has purchased Morphic Holding for $3.2 billion, intending to leverage its expertise in the field of gastroenterology. Fundz records the date the transaction was first publicly reported, sourced from filings and company announcements.
What does Morphic Therapeutic do?
Morphic Therapeutic is a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases. It is privately held, operating in Biotechnology, and is based in Waltham.
This company was part of an acquisition. Fundz tracks who bought whom, and who to call on both sides.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.